Anyone pointing to the Avastin/FDA example in CRC as a likely parallel of Provenge's BLA path without also pointing to the Avastin/FDA example in adjuvant breast cancer use is being misleading. Furthermore, IMO, that misleading is deliberate.
Wall - care to expand on the deliberation part? Are there some nefarious motives beyond the usual over-enthused cheerleading?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.